At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 925 enrolled
Drug / intervention
nivolumab +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
In Brief
A Phase 3 clinical trial evaluating nivolumab, ipilimumab, and 1 other intervention for Non-Small Cell Lung Cancer (NSCLC). Completed, enrolled 925 participants across 183 sites in 27 countries.
Detailed Summary
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer (NSCLC)
CountriesArgentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Germany, Greece, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Russia, Singapore, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedJul 2019
Enrollment StartOct 2019
Primary CompletionMar 2024
Study CompletionNov 2024
TodayJul 2026
First PostedJul 19, 2019
Enrollment StartOct 8, 2019
Primary CompletionMar 22, 2024
Study CompletionNov 26, 2024
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 7.0 years ago
Interventions
nivolumabbiological
Specified dose on specified days
ipilimumabbiological
Specified dose on specified days
durvalumabbiological
Specified dose on specified days